Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 30, 2005

View Archived Issues

Rats receiving CRF1 antagonist show reduction in submissive behavior

Ligand updates status of inhouse and partnered programs

Efficacy of LJ-529 in ER-negative breast cancer models

SPC-2968, an HIF-1 inhibitor, in preparation for initial clinical studies in 2006

Preclinical efficacy reported for GI-5005, a therapeutic vaccine for chronic hepatitis C infection

Enzon Pharmaceuticals and Micromet end research collaboration

European Commission approval for Teva's acquisition of Ivax

PharmaGap and OHSU Cancer Institute to collaborate on PKC inhibitors

GSK and Institut Pasteur collaborate to develop AIDS vaccine

American Pharmaceutical Partners to merge with American Bioscience

BioCryst submits IND for injectable formulations of peramivir

Enrollment completed in phase III study of Entereg in postoperative ileus

Phase III trials begin for PF-3512676 for NSCLC

Leo Pharma and Foamix to develop medicated foams for psoriasis

Agile completes phase II study for low estrogen contraceptive patch

Quadramet studied in combination with bortezomib for multiple myeloma

Neuren signs memorandum of understanding for Glypromate phase III trial

GW-610: new anticancer agent with potent and selective profile

New class of selective, orally active MEK1/2 inhibitors for cancer therapy

Feasibility of Syk kinase inhibition with R-406 demonstrated

Studies suggest benefit of IL-1 TRAP in atherosclerosis, CIAS1-associated syndromes

Ambrisentan beneficial in patients with connective tissue diseases and PAH

Obese, dyslipidemic subjects lose weight on rimonabant

Solvay suspends regulatory activities for cilansetron in U.S.

New antihepatitis C agents described in recent GSK patent

Novel agents for diabetes and related complications reported in recent patent literature

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
AI drug developer Insilico to raise $292 million in Hong Kong IPO
BioWorld
Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...